The COVID-19 pandemic has been declared as a public health emergency of international concern. It was thought of as a mild form of disease or asymptomatic infection in children and young adults. But the recently evolved multi-inflammatory syndrome associated with COVID-19 infection (MIS-C) reported in patients less than 21 years is a serious concern in this age group. The World Health Organization (WHO) and the Centre for Disease Control (CDC) have put forward the case definition and management guidelines for the same recently. Here, we report uveitis as the presenting symptom of MIS-C, which is not included in the case definition of MIS-C.
A 14-year-old girl from Medinipur presented to us with complaints of fever, redness and tearing of eyes, and headache for 10 days. She had come in contact with two COVID-19 positive cases (grandfather and uncle living in the same household) 4 weeks prior to the onset of symptoms. She did not have any other significant illness in the past. On examination, she was conscious and oriented, had pallor, right posterior cervical lymphadenopathy (single, 2 × 1 cm size, tender, mobile, discrete) with bilateral nonpurulent conjunctival congestion with no limbal sparing, photophobia, oral mucosal erythema, and strawberry tongue. She was febrile and had tachypnea (38 breaths per min) and tachycardia (124 bpm) and was normotensive. Her weight (56 kg, +1 Z score) and height (158 cm, 0.49 Z score) with a body mass index (BMI) of 22.8 (0.98 Z score) were normal. Her systemic examination was normal. From the history and clinical examination, incomplete Kawasaki disease and MIS-C were considered as provisional diagnoses with possible anterior uveitis – the cause for which was unclear. Laboratory investigations revealed anemia, hypoalbuminemia, and elevated inflammatory markers – erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and Serum Ferritin are shown in Table 1. COVID-19 RT-PCR at admission from the nasopharyngeal swab was negative. Ophthalmological examination revealed normal 6/6 visual acuity and color vision, bilateral nongranulomatous anterior uveitis with the presence of few KPs with Grade 1 cells. There was no flare and vitreous cells/scleritis. There was bilateral papillitis/disc edema. The retinal vessels were normal with no evidence of vasculitis. B-scan was done, and the report was normal. Magnetic resonance imaging (MRI) of the brain with orbit was done, which showed a normal optic nerve sheath diameter (ONSD) and no evidence of demyelination [Fig. 1a and b]. Topical steroids were started in view of anterior uveitis. A possibility of incomplete Kawasaki disease too was considered as the child had fever for more than 5 days with bilateral bulbar conjunctival congestion, oral mucosal erythema with strawberry tongue, unilateral cervical lymphadenopathy, elevated ESR, CRP, anemia, leukocytosis, and hypoalbuminemia. She was given Intravenous Immunoglobulin (IVIg) at a dose of 2 grams per kg and was started on aspirin. An echocardiogram did not show any coronary artery dilatation. After 48 h of IVIg, she continued to have retroorbital pain and developed photophobia as a new symptom in spite of fever subsidence. Her inflammatory markers had shown a rising trend. In view of the pandemic and close contact with COVID-19 patients, COVID-19 antibody titer (Anti-SARS CoV 2 Reflex IgG) was done, which was significantly elevated (36.31, Normal <1). Due to the persistence of eye symptoms, elevated inflammatory markers, and high IgG antibody titers for COVID-19, she was given oral steroids at a dose of 2 g/kg/day. Within 48 h of oral steroids, she showed marked improvement in eye symptoms as well as a decrease in the inflammatory marker levels. At discharge, she was well, and oral steroids were continued for 2 weeks, and ocular steroids were gradually tapered and stopped over 1 month. On follow-up at 3 months after discharge, repeat echocardiography was done which was normal, and there was normal vision with no optic disc pallor.
MIS-C is a newly defined entity related to COVID-19 infection. With quite variable clinical presentation, the complete clinical and pathological process is still being studied. Usually, it presents within 1 to 6 weeks of exposure to or infection with COVID-19 (1), which was 4 weeks in our case. She had clinical features suggestive of Kawasaki disease like mucosal erythema, unilateral lymphadenopathy, and bilateral conjunctival congestion, although her age was not typical for Kawasaki disease. Uveitis is reported in 66% of children with Kawasaki disease by Burns et al. However, our child did not show clinical improvement after IVIg administration, and interestingly her inflammatory markers, which were being monitored, showed further elevation [Fig. 2]. Hence, MIS-C was considered, and she responded well to oral steroids. Another supporting evidence was significant neutrophilia (83–85%), which is common in MIS-C and rare in Kawasaki disease. Interleukin 6 levels on Day 3 of admission, even after administration of IVIg worsened to levels of 5500 pg/ml, which has not been reported in MIS-C to date.
In the current scenario, where COVID-19 infection is rapidly spreading, it is essential to have a strong suspicion of MIS-C in children who present with fever, mucus membrane changes, and eye changes. Although conjunctivitis is classically mentioned in the definition, iridocyclitis or uveitis is a symptom that has not been previously reported as a symptom associated with the MIS-C complex in children; however, two reports are there in adults more than 40 years of age. The pathophysiology behind the inflammatory process in MIS-C is to be understood completely. Pathogenesis of uveitis caused by inflammatory diseases may be due to molecular mimicry, in which the infectious agent cross-reacts with ocular specific antigens, but the exact mechanism is not completely known. However, both the processes are unregulated immune-mediated inflammatory states which can well explain uveitis also as a presenting symptom in MIS-C. The possible cause of papillitis in our case could be capillaritis or small-vessel vasculitis of the disc vessels.
Management guidelines for MIS-C is IVIg, followed by steroid therapy in those who are unresponsive, followed by biologicals like tocilizumab. Our child required IVIg followed by steroids for complete recovery.
In the present scenario, we intend to convey that in any child or young adolescent presenting with symptoms of uveitis or any other immune-mediated symptoms, the possibility of MIS-C needs to be considered because unknown manifestations are more than known typical manifestations in COVID-19.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
1. Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, et al. COVID-19 associated Multisystem inflammatory syndrome in children (MIS-C) guidelines;a Western New York approach Prog Pediatr Cardiol 2020 101232 doi:10.1016/j.ppedcard. 2020.101232 Online ahead of print
2. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents:A systematic review JAMA Pediatr 2020 174 882 9
3. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents Lancet Infect Dis 2020 20 e276 88
4. Yu JJ Diagnosis of incomplete Kawasaki disease Korean J Pediatr 2012 55 83 7
5. Burns JC, Joffe L, Sargent RA, Glode MP Anterior uveitis
associated with Kawasaki syndrome Pediatr Infect Dis 1985 4 258 61
6. Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children:A systematic review EClinicalMedicine 2020 26 100527
7. Shaigany S, Gnirke M, Guttmann A, Chong H, Meehan S, Raabe V, et al. An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19 Lancet 2020 396 e8 10
8. Bettach E, Zadok D, Weill Y, Brosh K, Hanhart J Bilateral anterior uveitis
as a part of a multisystem inflammatory syndrome secondary to COVID-19 infection J Med Virol 2021 93 139 40
9. Rowley AH Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children Nat Rev Immunol 2020 20 453 54
10. Wildner G, Diedrichs-Möhring M Molecular Mimicry and Uveitis
Front Immunol 2020 11 580636
11. Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, et al. PIMS-TS National Consensus Management Study Group A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS):Results of a national Delphi process Lancet Child Adolesc Health 2021 5 133 41